Literature DB >> 21905786

Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens.

Ben Burrowes1, David R Harper, Joseph Anderson, Malcolm McConville, Mark C Enright.   

Abstract

The use of bacteriophages (phages) to treat bacterial infections, known as phage therapy, has a history substantially longer than that of antibiotics, yet these drugs have been the treatment of choice in the West for over 60 years owing to efficacy, low toxicity and ease of production. Bacteria are becoming increasingly resistant to antibiotics while efforts to discover new agents have drastically reduced. Phages have co-evolved with their hosts over billions of years and have acquired mechanisms to counter bacterial defences such as extracellular biofilm production, which severely reduces the effectiveness of conventional antibiotics. Recent animal and human trials show phages to be safe, well-tolerated agents with a bright future as an alternative to chemical agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21905786     DOI: 10.1586/eri.11.90

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  63 in total

Review 1.  Bacteriophage therapy against Enterobacteriaceae.

Authors:  Youqiang Xu; Yong Liu; Yang Liu; Jiangsen Pei; Su Yao; Chi Cheng
Journal:  Virol Sin       Date:  2015-02-03       Impact factor: 4.327

Review 2.  Bacteriocins - a viable alternative to antibiotics?

Authors:  Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Nat Rev Microbiol       Date:  2012-12-24       Impact factor: 60.633

Review 3.  Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era.

Authors:  Maria Kostakioti; Maria Hadjifrangiskou; Scott J Hultgren
Journal:  Cold Spring Harb Perspect Med       Date:  2013-04-01       Impact factor: 6.915

4.  Synergistic antimicrobial activity of bacteriophages and antibiotics against Staphylococcus aureus.

Authors:  Ara Jo; Tian Ding; Juhee Ahn
Journal:  Food Sci Biotechnol       Date:  2016-06-30       Impact factor: 2.391

5.  Combined use of bacteriophage K and a novel bacteriophage to reduce Staphylococcus aureus biofilm formation.

Authors:  D R Alves; A Gaudion; J E Bean; P Perez Esteban; T C Arnot; D R Harper; W Kot; L H Hansen; M C Enright; A Tobias A Jenkins
Journal:  Appl Environ Microbiol       Date:  2014-08-22       Impact factor: 4.792

Review 6.  Phage Therapy in the Era of Synthetic Biology.

Authors:  E Magda Barbu; Kyle C Cady; Bolyn Hubby
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

Review 7.  Biofilm control with natural and genetically-modified phages.

Authors:  Amir Mohaghegh Motlagh; Ananda Shankar Bhattacharjee; Ramesh Goel
Journal:  World J Microbiol Biotechnol       Date:  2016-03-01       Impact factor: 3.312

Review 8.  Managing urinary tract infections through phage therapy: a novel approach.

Authors:  Shikha Malik; Parveen Kaur Sidhu; J S Rana; Kiran Nehra
Journal:  Folia Microbiol (Praha)       Date:  2019-09-07       Impact factor: 2.099

9.  Effect of a genetically engineered bacteriophage on Enterococcus faecalis biofilms.

Authors:  Justine Monnerat Tinoco; Bettina Buttaro; Hongming Zhang; Nadia Liss; Luciana Sassone; Roy Stevens
Journal:  Arch Oral Biol       Date:  2016-07-06       Impact factor: 2.633

10.  Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine.

Authors:  Damien Maura; Matthieu Galtier; Chantal Le Bouguénec; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.